IRCT20200510047383N1 IRCT 2020-05-15 Arak University of Medical Sciences Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19 patients Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapy 2020-05-21 anticipated 100 Complete https://irct.ir/trial/48024 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Statistical software using block randomization method, Blinding description: For blinding, the person in charge of data collection and analysis are unaware of the grouping. 3 covid-19 disease. Intervention 1: Intervention group: Take tocilizumab. This group is given a dose of 8 mg per kilogram of body weight tocilizumab up to a maximum dose of 800 mg. If the symptoms worsen or do not improve, another dose is injected. If side effects occur, the complication is recorded and then the patient is removed from the study. Intervention 2: Control group: Receive standard multi drug protocol. Yes - There is a plan to make this available What will be shared: The findings will be submitted a related journal for peer review and possible publication When: In less than a year To whom: Findings are supposed to be published. Data will be available upon the request from the corresponding author Conditions: After publication upon the request from the corresponding author for meta analysis where a full right to the authorship is preserved Where to obtain: Upon the request from the corresponding author How to obtain: Describe the design of the research where the data is supposed to be available. We will be asking a full access to the whole data and will be participating in the analysis and interpretation and publication of the study Comments: